Bristol Myers Squibb Canada (BMS) has updated the Canadian product monograph for BREYANZI® (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor T (CAR T) cell therapy. The update reduces the duration of certain post-treatment monitoring and activity restrictions for eligible patients following infusion.

The revised guidance lowers the recommended duration for patients to remain in close proximity to a specialized treatment centre from 28 days to 14 days following infusion. Additionally, driving restrictions have been reduced from eight weeks to four weeks.

Clinical decisions regarding patient discharge and ongoing monitoring will continue to be determined by the treating healthcare professional based on individual patient needs.

Bristol Myers Squibb appointed Mayada Al-Ahmad as the General Manager for Saudi Arabia and Gulf Countries effective June 1, 2026. She will lead the affiliate spanning Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, and Jordan. The appointment aims to advance the company's mission to deliver transformative medicines to patients across the region.

Michelle Calope, Senior Vice President and Head of Intercontinental Markets at Bristol Myers Squibb, stated that Al-Ahmad's deep understanding of the Saudi and Gulf markets positions her well to lead the affiliate into its next phase of growth. Her leadership is expected to align with national and regional health transformation priorities.

Al-Ahmad brings over 24 years of progressive leadership experience in the pharmaceutical industry. Her background spans commercial, strategic, and country management functions across the Middle East, Africa, Türkiye, Russia, and Intercontinental markets. She holds broad therapeutic expertise in Oncology, Hematology, Cardiovascular, Neuroscience, and Diabetes.

Commenting on her appointment, Mayada Al-Ahmad expressed enthusiasm for leading Bristol Myers Squibb's efforts in the region. She emphasized her commitment to delivering innovative medicines and making a meaningful difference in patients' lives. Al-Ahmad looks forward to collaborating with the team and partners to further health and scientific advancement.

Key Details of the Appointment

Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases.